Antifungal Drug Discovery: The Process and Outcomes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
New data suggest that the global incidence of several types of fungal diseases have traditionally been under-documented. Of these, mortality caused by invasive fungal infections remains disturbingly high, equal to or exceeding deaths caused by drug-resistant tuberculosis and malaria. It is clear that basic research on new antifungal drugs, vaccines and diagnostic tools is needed. In this review, we focus upon antifungal drug discovery including in vitro assays, compound libraries and approaches to target identification. Genome mining has made it possible to identify fungal-specific targets; however, new compounds to these targets are apparently not in the antimicrobial pipeline. We suggest that 'repurposing' compounds (off patent) might be a more immediate starting point. Furthermore, we examine the dogma on antifungal discovery and suggest that a major thrust in technologies such as structural biology, homology modeling and virtual imaging is needed to drive discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Essential Gene Identification and Drug Target Prioritization in Aspergillus fumigatus
Hu, W., Sillaots, S., Lemieux, S., Davison, J., Kauffman, S., Breton, A., Linteau, A., Xin, C., Bowman, J., Becker, J., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030024 · Cited by 237
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Confronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147
Rodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Dolan, K., Montgomery, S., Buchheit, B., DiDone, L., Wellington, M., & Krysan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01564-08 · Cited by 112
Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast
Ericson, E., Gebbia, M., Heisler, L. E., Wildenhain, J., Tyers, M., Giaever, G., & Nislow, C. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000151 · Cited by 89
Lamoth, F., Juvvadi, P. R., Gehrke, C., & Steinbach, W. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01857-12 · Cited by 88
Lamoth, F., Juvvadi, P. R., Gehrke, C., Asfaw, Y. G., & Steinbach, W. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit530 · Cited by 62
Cited by
Paulussen, C., Hallsworth, J. E., Álvarez‐Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H., & Lievens, B. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12367 · Cited by 334
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
“The mortality rate was much greater than that of malaria or tuberculosis [7–9].”
Candida albicans the main opportunistic pathogenic fungus in humans
Macias-Paz, I. U., Pérez-Hernández, S., Tavera-Tapia, A., Luna-Arias, J. P., Guerra-Cárdenas, J. E., & Reyna-Beltrán, E. (2023) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2022.08.003 · Cited by 141
“Fungal infections cause about 1.7 million deaths worldwide per year mainly in immunocompromised individuals with two or more pathological conditions 6,42 The incidence of infections caused by the genus Candida has steadily increased since the 1970s perhaps due to an increased risk of opportunistic…”
BackgroundInfluentialThe Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
System-level impact of mitochondria on fungal virulence: to metabolism and beyond
Calderone, R., Li, D., & Traven, A. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov027 · Cited by 101
Self-citation
Metadata
- Authors
- Calderone, R., Sun, N., Gay-Andrieu, F., Groutas, W., Weerawarna, P., Prasad, S., Alex, D., & Li, D.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2014-06
- Volume
- 9
- Issue
- 6
- Pages
- 791-805
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2119391289
- Cited by
- 97
- References
- 20
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.